New Cancer Therapy from Indian Scientists Target Patients Resistant to Current Treatments

Published On 2024-10-14 03:15 GMT   |   Update On 2024-10-14 03:15 GMT
Scientists at the Indian Association for the Cultivation of Science (IACS), Kolkata, an autonomous institute of the Department of Science and Technology, have developed a novel therapy that could be a potential precision medicine especially for those resistant to current cancer remedies. The team identified a promising new target for cancer treatment by activating a DNA repair enzyme called TDP1, suggesting a combination therapy. To find an alternative treatment, the team probed how cancer cells repair DNA during cell division and respond to chemotherapy that targets the enzyme Top1, often leading to drug resistance.
The research published in The EMBO Journal highlights two key proteins --- Cyclin-dependent kinase 1 (CDK1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1). The study showed that cancer cells can counteract the effect of existing drugs by activating TDP1 -- a DNA repair enzyme -- allowing them to survive, said the team led by Benu Brata Das from the varsity. "By targeting both Cyclin-dependent kinase 1 and Tyrosyl-DNA Phosphodiesterase 1, we can potentially overcome resistance and improve treatment effectiveness," Das said.
Advertisement
The study suggests that using CDK1 inhibitors -- such as avotaciclib, alvocidib, roniciclib, riviciclib, and dinaciclib -- alongside Top1 inhibitors could enhance cancer cell killing. The study points to a promising avenue for precision medicine in treating cancers, especially those resistant to current therapies.
Full View
Tags:    
Article Source : EMBO Journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News